Cantor Fitzgerald initiated coverage on BioCryst Pharma with a new price target

4/29/25 8:10:45 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Cantor Fitzgerald initiated coverage of BioCryst Pharma with a rating of Overweight and set a new price target of $20.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BCRX

Date	Price Target	Rating	Analyst
4/29/2025	$20.00	Overweight	Cantor Fitzgerald
2/25/2025	$15.00	Outperform	Wedbush
11/20/2023	$10.00	Overweight	JP Morgan
9/18/2023	$9.00 → $10.00	Sector Perform → Outperform	RBC Capital Mkts
8/4/2023	$11.00	Hold → Buy	Jefferies
7/13/2023	$10.00	Neutral → Buy	BofA Securities
2/22/2023	$14.00	Hold → Buy	Needham
11/2/2022	$14.00 → $16.00	In-line → Outperform	Evercore ISI